Understanding Your Diagnosis: ICOSLG Deficiency
At a Glance
ICOSLG deficiency is an exceptionally rare inherited combined immune disorder that can cause recurrent respiratory and DNA-virus infections, low protective antibodies, and abnormal immune-cell function. Because only a few cases are known, specialists tailor monitoring and treatment to each person.
Receiving a diagnosis of Late-Onset Combined Immunodeficiency due to ICOSLG deficiency means you are among a very small group of people globally with this specific condition. Because this is an exceptionally rare inborn error of immunity (a genetic condition that affects how the immune system is built and functions), you may find that many doctors have never encountered it [1][2].
This condition is autosomal recessive, meaning it only occurs when a person inherits two copies of a specific non-working (pathogenic) gene—one from each parent [1]. In the scientific literature, much of what is known comes from the deep study of a single patient, which means the full “spectrum” of how this disease looks in different people is still being discovered [1][2].
Defining ICOSLG Deficiency
ICOSLG deficiency is classified as a combined immunodeficiency (CID). This means it does not just affect one part of your immune system; instead, it impacts multiple “branches” that normally work together to fight off germs:
- T cells: These act as the “generals” of the immune system, directing the response and killing infected cells. In this condition, T cells may have trouble being activated or providing “help” to other cells [1][3].
- B cells: These cells produce antibodies (protective proteins). People with this deficiency often have low levels of switched-memory B cells, which are the cells that “remember” how to fight a germ if you see it again [1][4].
- Neutrophils: These are the “first responders” that rush to the site of an infection. Research suggests that in this condition, neutrophils may have difficulty migrating out of the bloodstream and into the tissues where they are needed [1].
Why ICOSL is Unique
You may hear your care team talk about ICOS deficiency, which sounds similar but is caused by a different genetic “glitch.” While they share some features, they are distinct:
- The Partnership: Think of ICOS and ICOSL as a lock and a key. ICOS is the “lock” found on T cells, and ICOSLG provides the “key” (the ligand) usually found on B cells or the lining of blood vessels [1][2].
- The Result: When they meet, they send a signal that tells the immune system to create high-quality antibodies and memory cells. In ICOSLG deficiency, the “key” is missing or broken. This impairs the signal, leading to low levels of protective antibodies (hypogammaglobulinemia) [1].
- Distinctions: While ICOS deficiency has been studied in more patients and is known to sometimes lead to cancer or severe inflammatory issues (enteropathy), these complications have not been established as features of ICOSLG deficiency, which is currently more limited to infections and cell-movement problems [4][5].
What to Expect: Knowns and Unknowns
Because this condition is so rare, your clinical team will focus on what has been documented in the primary research case, while acknowledging your experience may differ:
What Has Been Reported:
- Infection Patterns: The deeply characterized patient experienced recurrent respiratory infections (like sinus or lung infections) [1][2].
- Viral Susceptibility: There is a specific vulnerability to DNA viruses that affect “epithelial barriers” (the skin and linings of the body). In the reported case, this included persistent HPV (warts) or severe HSV (cold sores) [2].
- Immune Abnormalities: Blood tests in the reported case showed panlymphopenia (low levels of all types of lymphocytes) and moderate neutropenia (a low count of neutrophils) [1].
What Remains Uncertain:
- Long-Term Outlook: Because so few cases have been tracked over many decades, the long-term prognosis (expected course of the disease) is not yet fully defined.
- The Full Spectrum: We do not yet know if every person with this genetic variant will have the exact same symptoms or timeline. Age of onset and severity are not definitively known for a broad population.
- Optimal Treatment: There is no established “standard” protocol specifically for ICOSLG deficiency yet. Treatments are tailored to your labs, such as using immunoglobulin replacement therapy to provide the antibodies your body isn’t making effectively [4].
Moving Forward with Your Care
Because your condition is a “frontier” of immunology, your most important tool is a specialized care team. This usually includes a clinical immunologist who has experience with rare genetic immune disorders. They will likely monitor your blood counts and antibody levels closely and may use preventive antibiotics or antiviral medications to protect your lungs and skin [4]. You may also consider genetic counseling to discuss carrier testing for relatives and reproductive options.
While the rarity of this diagnosis can feel isolating, it also means that your clinical data can contribute to the global understanding of the disease, helping doctors better treat others in the future.
Common questions in this guide
What is ICOSLG deficiency?
How is ICOSLG deficiency inherited?
What infections can occur with ICOSLG deficiency?
Is ICOSLG deficiency the same as ICOS deficiency?
Can ICOSLG deficiency affect vaccine responses?
What treatments are used for ICOSLG deficiency?
What is the long-term outlook for ICOSLG deficiency?
Get notified when new evidence is published on Late-onset combined immunodeficiency due to ICOSL deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (5)
- 1
Loss of human ICOSL results in combined immunodeficiency.
Roussel L, Landekic M, Golizeh M, et al.
The Journal of experimental medicine 2018; (215(12)):3151-3164 doi:10.1084/jem.20180668.
PMID: 30498080 - 2
ICOSL in host defense at epithelial barriers: lessons from ICOSLG deficiency.
Roussel L, Vinh DC
Current opinion in immunology 2021; (72()):21-26 doi:10.1016/j.coi.2021.03.001.
PMID: 33756276 - 3
Development of T follicular helper cell-independent nanoparticle vaccines for SARS-CoV-2 or HIV-1 by targeting ICOSL.
Zhang Y, Chen A, Li D, et al.
NPJ vaccines 2024; (9(1)):176 doi:10.1038/s41541-024-00971-4.
PMID: 39341822 - 4
14 Years after Discovery: Clinical Follow-up on 15 Patients with Inducible Co-Stimulator Deficiency.
Schepp J, Chou J, Skrabl-Baumgartner A, et al.
Frontiers in immunology 2017; (8()):964 doi:10.3389/fimmu.2017.00964.
PMID: 28861081 - 5
Expanding Clinical Phenotype and Novel Insights into the Pathogenesis of ICOS Deficiency.
Abolhassani H, El-Sherbiny YM, Arumugakani G, et al.
Journal of clinical immunology 2020; (40(2)):277-288 doi:10.1007/s10875-019-00735-z.
PMID: 31858365
This page is for informational purposes only and does not constitute medical advice. A clinical immunologist should interpret your ICOSLG results and tailor infection monitoring and treatment to your situation.